drugset / Trial / NCT07691606
A Study of ARC-02 in B-cell NHL
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Timeline
- Start
- 2026-06-04
- Primary completion
- 2029-01
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARC-02 | Unknown | — | Intravenous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |